Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Renal cell carcinoma Stories

2012-01-09 03:05:00

SAN FRANCISCO, January 9, 2012 /PRNewswire/ -- SFJ Pharma Ltd. II (President & CEO: Robert F. DeBenedetto, "SFJ") announced today that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial in Asia of Pfizer's investigational agent axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy. Axitinib is an oral and selective inhibitor of vascular...

2011-12-07 17:34:00

EAST HANOVER, N.J., Dec. 7, 2011 /PRNewswire/ -- Updated results of a Phase III study of Afinitor® (everolimus) tablets plus exemestane, a hormonal therapy, show everolimus provided additional time women with advanced breast cancer lived without their disease progressing (progression-free survival)(1). The study findings, which represent an additional five months of follow-up, were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium...

2011-12-05 13:06:47

Study published online today in Nature Genetics BGI, the world's largest genomics organization, announced that a study on frequent mutation of genes encoding ubiquitin-mediated proteolysis pathway (UMPP) components in clear cell renal cell carcinoma (ccRCC) is published online today in Nature Genetics. In addition to BGI, co-leaders of the study included Peking University Shenzhen Hospital, Shenzhen Second People's Hospital, among others. The study reveals that alteration of UMPP may...

2011-10-25 09:40:54

Use of acetaminophen and nonaspirin nonsteroidal anti-inflammatory drugs was associated with a significantly increased risk for developing renal cell carcinoma, according to data presented at the 10th AACR International Conference on Frontiers in Cancer Prevention Research, held Oct. 22-25, 2011. Eunyoung Cho, Sc.D., assistant professor of medicine at Harvard Medical School and associate epidemiologist at Brigham and Women's Hospital in Boston, and colleagues conducted a preliminary...

2011-10-23 07:00:00

Kidney Cancer Association commits $10,000.00 to research in honor of Dr. Linehan's work. Chicago, Illinois (PRWEB) October 23, 2011 W. Marston Linehan, M.D., Branch Chief, Urologic Oncology Branch, Center for Cancer Research at the National Cancer Institute (NCI), was honored at the 10th International Kidney Cancer Symposium held recently in Chicago for his career-long commitment to advancing breakthroughs in kidney cancer research. In addition to delivering the Andrew C. Novick Memorial...

2011-10-14 16:30:00

BROOMFIELD, Colo., Oct. 14, 2011 /PRNewswire/ -- Data presented at the 10th International Kidney Cancer Symposium being held in Chicago, IL show that the pretreatment blood-based test, VeriStrat, was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies, sunitinib (Sutent®) and erlotinib (Tarceva®), by survival outcomes. Patients who tested VeriStrat Good had significantly longer progression free...

2011-10-07 10:02:03

Medical researchers are demonstrating that Office of Naval Research (ONR)-funded software developed for finding and recognizing undersea mines can help doctors identify and classify cancer-related cells. “The results are spectacular,” said Dr. Larry Carin, professor at Duke University and developer of the technology. “This could be a game-changer for medical research.” The problem that physicians encounter in analyzing images of human cells is surprisingly...

2011-09-25 17:07:00

EAST HANOVER, N.J., Sept. 25, 2011 /PRNewswire/ -- A pivotal Phase III study shows Afinitor® (everolimus) tablets plus exemestane, a hormonal therapy, more than doubled the time women lived without tumor growth (progression-free survival; PFS) and significantly reduced the risk of cancer progression by 57% versus exemestane alone in patients with advanced breast cancer(1). "Everolimus is the first drug to show significant efficacy when combined with hormonal therapy in...

2011-09-23 10:33:00

EAST HANOVER, N.J., Sept. 23, 2011 /PRNewswire/ -- A Phase III study of Afinitor® (everolimus) tablets* in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors. Findings from the trial, known as EXIST-2, were presented today at the International TSC Research Conference...

2011-09-12 23:31:47

Long-term use of nonaspirin anti-inflammatory drugs (NSAIDs) is associated with an increased risk of renal cell cancer (RCC), according to a report in the September issue of Archives of Internal Medicine, one of the JAMA/Archives journals. According to background information in the article, in the United States, kidney cancer is the seventh leading type of cancer among men and the ninth leading type of cancer among women. The most common type of kidney cancer, renal cell cancer, accounts...